Another KRAS Inhibitor Holds Its Own
- PMID: 33115812
- DOI: 10.1158/2159-8290.CD-NB2020-098
Another KRAS Inhibitor Holds Its Own
Abstract
According to the KRYSTAL-1 study, the KRASG12c inhibitor adagrasib, also known as MRTX849, is largely well tolerated and shows considerable efficacy in patients with non-small cell lung cancer harboring this mutation. The drug is also active, albeit more modestly, in colorectal cancer and several other solid tumor types.
©2020 American Association for Cancer Research.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
